New test can detect cervical cancer overnight
British and American scientists have created a new test to detect cervical cancer, reports The Telegraph.
The Cobas test is considered to be more accurate than the currently used smear test – thought to detect only one in three cases of cervical cancer. The Cobas test is thought to pick up almost all cases.
The difference between the two tests rests on what they are testing for: the smear test detects abnormal cell growth, while the new test detects the presence of HPV or the human papilloma virus, which triggers the abnormal growth of cells.
Scientists believe that screening for HPV will allow doctors to detect cases of cervical cancer earlier. This is especially important for cervical cancer patients as the poor survival rate of the disease is directly linked to the low detection rate and late diagnosis of the disease.
47,000 women were involved in the trials, developed by pharmaceuticals giant Roche, which found that the Cobas test detected the HPV virus in 10% of women who had been cleared through a smear test. It is thought that the new test could be rolled out in doctors’ surgeries within a year.
Although the creators of the test are claiming that its introduction ‘could save thousands’, Cancer Research UK assert that more investigation of the test needs to take place before it is rolled out in the UK, in order to “answer remaining questions about its use in practice”.
“If the NHS decided to change from the cervical screening test to this newer method, there would likely be no going back. So there needs to be hard evidence that the HPV test would improve the screening programme,” said Henry Stowecroft of Cancer Research UK.
Read the full story in the Telegraph.











